Candel Therapeutics, Inc. posts new long term trial results for aglatimagene besadenovec

Candel Therapeutics, Inc. posts new long term trial results for aglatimagene besadenovec
Candel long term prostate data

Candel Therapeutics, Inc. has unveiled new long term follow up data from its phase 3 trial of aglatimagene besadenovec (CAN-2409) targeting localized prostate cancer.

Chief Executive Officer Paul Peter Tak engaged in an interview with Endpoints News reporter Nicole DeFeudis to discuss the clinical findings. The update highlights the company’s continued progress in immunotherapy and cancer research, with attention focused on the therapy’s impact in prostate cancer management. Further peer-reviewed publication and clinical commentary are anticipated as the field digests these trial outcomes.

Earlier results from Candel’s phase 3 prostate cancer trial showed an 80.4 percent complete response rate, surpassing outcomes in the placebo group, according to a prior report. At BioEquityEurope this year, CEO Paul Peter Tak called for strengthening patient engagement to drive innovation in drug discovery, as noted in a previous panel discussion. The company continues to advance its research pipeline alongside these ongoing clinical updates.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.